Form 8-K - Current report:
SEC Accession No. 0001683168-23-003312
Filing Date
2023-05-15
Accepted
2023-05-15 08:36:24
Documents
14
Period of Report
2023-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm   iXBRL 8-K 27097
2 PRESS RELEASE DATED MAY 15, 2023 cns_ex9901.htm EX-99.1 19933
6 GRAPHIC image_001.jpg GRAPHIC 4600
  Complete submission text file 0001683168-23-003312.txt   233848

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnsp-20230515.xsd EX-101.SCH 2962
4 XBRL LABEL FILE cnsp-20230515_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnsp-20230515_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3718
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 23918670
SIC: 2834 Pharmaceutical Preparations